@article{MTMT:34523817,
	title = {Tumour regression predicts better response to interferon therapy in melanoma patients. a retrospective single centre study.},
	url = {https://m2.mtmt.hu/api/publication/34523817},
	author = {Mezőlaki, Noémi and Baltás, Eszter and Ócsai, Henriette and Varga, Anita and Korom, Irma and Varga, Erika and Németh, István Balázs and Kis, Erika and Varga, János and Kocsis, Ádám László and Gyulai, Rolland Péter and Bukva, Mátyás and Kemény, Lajos and Oláh, Judit Magdolna},
	doi = {10.1097/CMR.0000000000000935},
	journal-iso = {MELANOMA RES},
	journal = {MELANOMA RESEARCH},
	volume = {34},
	unique-id = {34523817},
	issn = {0960-8931},
	abstract = {We hypothesise that regression may have an impact on the effectiveness of adjuvant IFN therapy, based on its role in the host immune response. Our purpose is to investigate regression and ulceration as prognostic factors in case of interferon-alpha (IFN)-treated melanoma patients. We followed 357 IFN-treated melanoma patients retrospectively, investigating progression-free survival (PFS) and overall survival (OS) depending on the presence of ulceration and regression. A Kaplan-Meier analysis was performed, and we used a Cox regression analysis to relate risk factors. The survival function of the Cox regression was used to measure the effect of regression and ulceration on PFS and OS depending on the Breslow thickness (T1-T4) of the primary tumour. Regression was significantly positively related to PFS ( P  = 0.0018, HR = 0.352) and OS ( P  = 0.0112, HR = 0.380), while ulceration showed a negative effect (PFS: P  = 0.0001, HR = 2.629; OS: P  = 0.0003, HR = 2.388). They influence survival independently. The most favourable outcome was measured in the regressed/non-ulcerated group, whereas the worse was in the non-regressed/ulcerated one. Of risk factors, Breslow thickness is the most significant predictor. The efficacy of regression is regardless of Breslow thickness, though the more favourable the impact of regression was in the thicker primary lesions. Our results indicate that regression is associated with a more favourable outcome for IFN-treated melanoma patients, whereas ulceration shows an inverse relation. Further studies are needed to analyse the survival benefit of regression in relation to innovative immune checkpoint inhibitors.},
	year = {2024},
	eissn = {1473-5636},
	pages = {54-62},
	orcid-numbers = {Baltás, Eszter/0000-0003-0357-7393; Gyulai, Rolland Péter/0000-0002-3286-8846; Bukva, Mátyás/0000-0002-5225-0285; Kemény, Lajos/0000-0002-2119-9501}
}

@article{MTMT:34405844,
	title = {Effect of inflammatory microenvironment on the regenerative capacity of adipose-derived mesenchymal stem cells},
	url = {https://m2.mtmt.hu/api/publication/34405844},
	author = {Szűcs, Diána and Miklós, Vanda and Monostori, Tamás and Guba, Melinda and Kun-Varga, Anikó and Póliska, Szilárd and Kis, Erika and Bende, Balázs and Kemény, Lajos and Veréb, Zoltán},
	journal-iso = {IMMUNOLÓGIAI SZEMLE},
	journal = {IMMUNOLÓGIAI SZEMLE},
	volume = {15},
	unique-id = {34405844},
	issn = {2061-0203},
	year = {2023},
	pages = {35-35},
	orcid-numbers = {Veréb, Zoltán/0000-0002-9518-2155}
}

@article{MTMT:34340896,
	title = {Immunszupprimált betegek multiplex bőrdaganatainak elektrokemoterápiás kezelése [Electrochemotherapy for multiple cutaneous tumors in immunosuppressed patients]},
	url = {https://m2.mtmt.hu/api/publication/34340896},
	author = {Rózsa, Petra and Ágoston, Dóra and Szederkényi, Edit and Ócsai, Henriette and Baltás, Eszter and Vass, Gábor and Kemény, Lajos and Oláh, Judit Magdolna and Kis, Erika},
	doi = {10.1556/650.2023.32852},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {164},
	unique-id = {34340896},
	issn = {0030-6002},
	abstract = {Introduction: The risk of cutaneous malignancies is significantly higher in immunosuppressed patients compared to the general population. These high-risk skin tumors tend to be aggressive, multiplex, rapidly growing lesions. It is common to see local recurrence after surgical excision. Multiplex tumors are difficult to treat, especially in the head/ neck region.Objective: Amongst the standard treatment options, electrochemotherapy can be a suitable option. Our aim was to evaluate the efficacy of electrochemotherapy in immunocompromised patients.Method: In 9 immunosuppressed patients, 118 (average: 13, n = 5-27) non-melanoma skin tumors were treated with electrochemotherapy with intravenous administration of bleomycin, according to the ESOPE criteria.Results: The median follow-up was 15 months. 6 months after the treatment, the objective response rate was 96%. We observed complete response in 88%, partial response in 8% and progressive disease in 2% of the treated lesions. In 2%, the response was not evaluable.Conclusion: In immunocompromised patients, electrochemotherapy is an effective and safe therapeutic option for non-melanoma skin tumors. In order to provide more ideal management for this special sub-group, prevention, multidisciplinary approach and optimized immunosuppressive therapy is essential.},
	keywords = {ELECTROCHEMOTHERAPY; immunosuppressed patients; non-melanoma skin tumors},
	year = {2023},
	eissn = {1788-6120},
	pages = {1462-1468},
	orcid-numbers = {Szederkényi, Edit/0000-0002-3583-6874; Baltás, Eszter/0000-0003-0357-7393; Vass, Gábor/0000-0003-0787-8679; Kemény, Lajos/0000-0002-2119-9501}
}

@article{MTMT:34160965,
	title = {Efficacy of Electrochemotherapy in Breast Cancer Patients of Different Receptor Status: The INSPECT Experience},
	url = {https://m2.mtmt.hu/api/publication/34160965},
	author = {Di, Prata C and Mascherini, M and Ross, AM and Silvestri, B and Kis, Erika and Odili, J and Fabrizio, T and Jones, RP and Kunte, C and Orlando, A and Clover, J and Kumar, S and Russano, F and Matteucci, P and Muir, T and de, Terlizzi F and Gehl, J and Grischke, EM},
	doi = {10.3390/cancers15123116},
	journal-iso = {CANCERS},
	journal = {CANCERS},
	volume = {15},
	unique-id = {34160965},
	year = {2023},
	eissn = {2072-6694}
}

@article{MTMT:34085618,
	title = {Effect of Inflammatory Microenvironment on the Regenerative Capacity of Adipose-Derived Mesenchymal Stem Cells},
	url = {https://m2.mtmt.hu/api/publication/34085618},
	author = {Szűcs, Diána and Miklós, Vanda and Monostori, Tamás and Guba, Melinda and Kun-Varga, Anikó and Póliska, Szilárd and Kis, Erika and Bende, Balázs and Kemény, Lajos and Veréb, Zoltán},
	doi = {10.3390/cells12151966},
	journal-iso = {CELLS-BASEL},
	journal = {CELLS},
	volume = {12},
	unique-id = {34085618},
	abstract = {Adipose-derived mesenchymal stem cells are increasingly being used in regenerative medicine as cell therapy targets, including in the treatment of burns and ulcers. The regenerative potential of AD-MSCs and some of their immunological properties are known from in vitro studies; however, in clinical applications, cells are used in non-ideal conditions and can behave differently in inflammatory environments, affecting the efficacy and outcome of therapy. Our aim was to investigate and map the pathways that the inflammatory microenvironment can induce in these cells. High-throughput gene expression assays were performed on AD-MSCs activated with LPS and TNFα. Analysis of RNA-Seq data showed that control, LPS-treated and TNFα-treated samples exhibited distinct gene expression patterns. LPS treatment increased the expression of 926 genes and decreased the expression of 770 genes involved in cell division, DNA repair, the cell cycle, and several metabolic processes. TNFα treatment increased the expression of 174 genes and decreased the expression of 383 genes, which are related to cell division, the immune response, cell proliferation, and differentiation. We also map the biological pathways by further investigating the most altered genes using the Gene Ontology and KEGG databases. Secreted cytokines, which are important in the immunological response, were also examined at the protein level, and a functional assay was performed to assess wound healing. Activated AD-MSC increased the secretion of IL-6, IL-8 and CXCL-10, and also the closure of wounds. AD-MSCs presented accelerated wound healing under inflammation conditions, suggesting that we could use this cell in clinical application.},
	year = {2023},
	eissn = {2073-4409},
	orcid-numbers = {Kemény, Lajos/0000-0002-2119-9501; Veréb, Zoltán/0000-0002-9518-2155}
}

@article{MTMT:34043904,
	title = {Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations. An International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report},
	url = {https://m2.mtmt.hu/api/publication/34043904},
	author = {Muir, Tobian and Bertino, Giulia and Groselj, Ales and Ratnam, Lakshmi and Kis, Erika and Odili, Joy and McCafferty, Ian and Wohlgemuth, Walter A and Cemazar, Maja and Krt, Aljosa and Bosnjak, Masa and Zanasi, Alessandro and Battista, Michela and de Terlizzi, Francesca and Campana, Luca G and Sersa, Gregor},
	doi = {10.2478/raon-2023-0029},
	journal-iso = {RADIOL ONCOL},
	journal = {RADIOLOGY AND ONCOLOGY},
	volume = {57},
	unique-id = {34043904},
	issn = {1318-2099},
	year = {2023},
	eissn = {1581-3207},
	pages = {141-149}
}

@article{MTMT:33928935,
	title = {Az SZTE Bőrgyógyászati és Allergológiai Klinikán a melanoma malignum sebészi kezelésében történt változások az elmúlt évtizedben [Changes in the surgical treatment of melanoma malignum at the Department of Dermatology and Allergology University of Szeged over the last decade]},
	url = {https://m2.mtmt.hu/api/publication/33928935},
	author = {Varga, Ákos and Bende, Balázs and Baltás, Eszter and Németh, István Balázs and Varga, Erika and Vass, Gábor and Kis, Erika and Oláh, Judit Magdolna and Varga, János and Kocsis, Ádám László},
	doi = {10.7188/bvsz.2023.99.2.6},
	journal-iso = {BVSZ},
	journal = {BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE},
	volume = {99},
	unique-id = {33928935},
	issn = {0006-7768},
	year = {2023},
	eissn = {2064-261X},
	pages = {122-124},
	orcid-numbers = {Baltás, Eszter/0000-0003-0357-7393; Vass, Gábor/0000-0003-0787-8679}
}

@article{MTMT:33928735,
	title = {Az elektrokemoterápia mérföldkövei [Milestones of electrochemotherapy]},
	url = {https://m2.mtmt.hu/api/publication/33928735},
	author = {Kis, Erika and Baltás, Eszter and Ócsai, Henriette and Csányi, Ildikó and Ottlakán, Aurél and Lázár, György ifj and Vass, Gábor and Ágoston, Dóra and Rózsa, Petra and Bottyán, Krisztina and Dalmády, Szandra and Nagy, András and Tóth-Molnár, Edit and Oláh, Judit Magdolna},
	doi = {10.7188/bvsz.2023.99.2.5},
	journal-iso = {BVSZ},
	journal = {BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE},
	volume = {99},
	unique-id = {33928735},
	issn = {0006-7768},
	year = {2023},
	eissn = {2064-261X},
	pages = {116-120},
	orcid-numbers = {Baltás, Eszter/0000-0003-0357-7393; Csányi, Ildikó/0000-0002-0766-5289; Ottlakán, Aurél/0000-0002-7743-7775; Lázár, György ifj/0000-0001-7155-2978; Vass, Gábor/0000-0003-0787-8679; Dalmády, Szandra/0000-0001-7362-5640; Tóth-Molnár, Edit/0000-0001-7989-1616}
}

@article{MTMT:33928341,
	title = {European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma},
	url = {https://m2.mtmt.hu/api/publication/33928341},
	author = {Campana, Luca G and Farronato, Sofia and Hodgetts, Jackie and Odili, Joy and Vecchiato, Antonella and Bracken, Alison and Baier, Susanne and Bechara, Falk G and Borgognoni, Lorenzo and Caracò, Corrado and Carvalhal, Sara and Covarelli, Piero and Clover, James and Eisendle, Klaus and Fantini, Fabrizio and Fierro, Maria Teresa and Farricha, Victor and Gregorelli, Chiara and Hafner, Jürg and Kunte, Christian and Gerlini, Gianni and Hessam, Schapoor and Mandalà, Mario and Piazzalunga, Dario and Quaglino, Pietro and Snoj, Marko and Ross, Alastair Mackenzie and Trigona, Béatrice and Moreno-Ramirez, David and Tauceri, Francesca and Peach, Howard and Rutkowski, Piotr and Muir, Tobian and de Terlizzi, Francesca and Patuzzo, Roberto and Mühlstädt, Michael and Dietrich, Karin-Almut and Mussack, Thomas and Matteucci, Paolo and Kis, Erika and Ascierto, Paolo and Sersa, Gregor and Valpione, Sara},
	doi = {10.1093/bjs/znad105},
	journal-iso = {BRIT J SURG},
	journal = {BRITISH JOURNAL OF SURGERY},
	volume = {110},
	unique-id = {33928341},
	issn = {0007-1323},
	year = {2023},
	eissn = {1365-2168},
	pages = {818-830},
	orcid-numbers = {Campana, Luca G/0000-0002-8466-8459; Ascierto, Paolo/0000-0002-8322-475X; Baltás, Eszter/0000-0003-0357-7393}
}

@article{MTMT:33807738,
	title = {Current Updates in Bleomycin-Based Electrochemotherapy for Deep-Seated Soft-Tissue Tumors},
	url = {https://m2.mtmt.hu/api/publication/33807738},
	author = {Ottlakán, Aurél and Lázár, György ifj and Oláh, Judit Magdolna and Nagy, András and Vass, Gábor and Vas, Márton Árpád and Pereira, Raissa and Kis, Erika},
	doi = {10.3390/electrochem4020019},
	journal-iso = {ELECTROCHEM},
	journal = {ELECTROCHEM},
	volume = {4},
	unique-id = {33807738},
	abstract = {Electrochemotherapy (ECT) has evolved significantly during the last decade, expanding treatment indications from superficial skin lesions to advanced-stage, deep-seated tumors in hard-to-reach areas. Electrodes have also shown steady technological improvement throughout the years. Besides standard and VEG (variable geometry electrode) electrodes, the introduction of laparoscopic electrodes has brought on a new era in ECT treatment, making the minimally invasive approach a reality. The exact role of ECT in the oncological dashboard is yet to be determined; however, increased tumor response, pain relief, and a low number of adverse events may yield the way for more widespread application of the technique with possible further inclusion of ECT in international oncological guidelines. The aim of this review is to give an overview on the current status of ECT in deep-seated tumor treatment and shed light on its emerging role in local anticancer therapy.},
	year = {2023},
	eissn = {2673-3293},
	pages = {282-290},
	orcid-numbers = {Ottlakán, Aurél/0000-0002-7743-7775; Lázár, György ifj/0000-0001-7155-2978; Vass, Gábor/0000-0003-0787-8679; Pereira, Raissa/0009-0005-0794-7410}
}